NCT02931071View on ClinicalTrials.gov

Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Fanconi Anemia
Interventions
DRUG

filgrastim

G-CSF (12 μg/Kg/12 h) 8 days.

DRUG

plerixafor

Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor

Trial Locations (2)

28009

Hospital Infantil Universitario Niño Jesus, Madrid

08035

Hospital Universitari Vall d'Hebron, Barcelona

All Listed Sponsors
collaborator

CIEMAT

UNKNOWN

collaborator

CIBERER

UNKNOWN

lead

Hospital Universitari Vall d'Hebron Research Institute

OTHER

NCT02931071 - Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1 | Biotech Hunter | Biotech Hunter